PCOS pathophysiology aligns mechanistically with GLP-1 RA therapy. Evidence supports weight, glycemic, and androgen improvements. Fertility considerations are critical.
Why mechanism fits
PCOS features insulin resistance, weight gain, anovulation, hyperandrogenism, metabolic dysfunction. GLP-1 addresses insulin resistance and weight directly; improvements cascade to androgen levels and menstrual regularity.
Evidence
Observational and small RCT data show weight loss, improved insulin sensitivity, reduced androgens, improved menstrual regularity. Larger phase 3 trials specific to PCOS are limited.
Critical fertility consideration
GLP-1 may restore ovulation in patients with weight-related anovulation. Unexpected pregnancy is well documented. Effective contraception is essential during therapy if pregnancy is not desired.
Tirzepatide + OCP interaction
Tirzepatide label recommends backup contraception for 4 weeks at initiation AND after each dose escalation due to potential reduction in OCP absorption. Critical for PCOS patients of reproductive age.
Pregnancy planning
If pregnancy desired: washout (sema ≥2 months, tirz ≥1 month before conception). Coordinate with reproductive endocrinology.
Long-term framing
PCOS is chronic. Weight regain after discontinuation (STEP-4) is likely. Plan for long-term therapy or structured maintenance. See PCOS condition page.